Answers are grounded in this paper and cite their sources.
The human anaphylatoxin C5a is a potent proinflammatory mediator generated during complement activation. C5a acts through the G-protein-coupled receptors C5aR1 and C5aR2, which are implicated in many immune-inflammatory diseases, and blocking C5a-C5aR1 signaling is a promising therapeutic strategy. Here we generate and characterize nanobodies, single-domain antibody fragments, that bind human and mouse C5a with high affinity and fall into two families recognizing non-overlapping epitopes. In cell assays, these nanobodies block C5a-induced receptor activation and downstream signaling. Crystallography shows that the antigen-binding loop of the highest-affinity nanobody mimics a turn in the extracellular amino-terminal region of C5aR1 and C5aR2, so that the nanobody competes with the receptor for the same surface of C5a. An antibody loop and a cell-surface receptor thus converge on analogous solutions for engaging the same ligand. These results inform our understanding of antibody-mediated inhibition of receptor agonists and identify nanobody-based C5a inhibitors as candidates to modulate C5a-driven inflammation.
No takes yet. Share an insight, caveat, or question.
Santos-López et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: